The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Effect of a Pharmaceutical Care Program on Vascular Risk Factors in Type 2 Diabetes
Open accessAbstract
OBJECTIVE—To examine the effect of a 12-month pharmaceutical care (PC) program on vascular risk in type 2 diabetes. RESEARCH DESIGN AND METHODS—We recruited 198 community-based patients randomized to PC or usual care. PC patients had face-to-face goal-directed medication and lifestyle counseling at baseline and at 6 and 12 months plus 6-weekly telephone assessments and provision of other educational material. Clinical, biochemical, and medication-related data were sent regularly to each patient’s physician(s). The main outcome measure was change in HbA1c. A diabetes-specific risk engine was used to estimate changes in 10-year coronary heart disease (CHD) and stroke risk in patients without a history of cardiovascular disease. RESULTS—At total of 180 patients (91%) completed the study. Mean (95% CI) reductions were greater in PC case subjects (n = 92) than control subjects (n = 88) for HbA1c (−0.5% [95% CI −0.7 to −0.3] vs. 0 [−0.2 to 0.2]) and systolic (−14 mmHg [−19 to −9] vs. −7 [−11 to −2]) and diastolic (−5 mmHg [−8 to −3] vs. −2 [−4 to 1]) blood pressure (P ≤ 0.043). The improvement in HbA1c persisted after adjustment for baseline value and demographic and treatment-specific variables. The median (interquartile range) 10-year estimated risk of a first CHD event decreased in the PC case subjects (25.1% [15.6–36.2] to 20.3 [14.6–30.2]; n = 42, P = 0.002) but not in the control subjects (26.1% [17.2–39.4] vs. 26.4 [16.7–38.0]; n = 52, P = 0.17). CONCLUSIONS—A 12-month PC program in type 2 diabetes reduced glycemia and blood pressure. Pharmacist involvement contributed to improvement in HbA1c independently of pharmacotherapeutic changes. PC could prove a valuable component of community-based multidisciplinary diabetes care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 8×
“One indication of the effectiveness of our approach comes from U.K. Prospective Diabetes Study (26) epidemiological analyses that equate a 0.5% HbA 1c reduction to an estimated 7% reduction in the risk of myocardial infarction and an estimated 12% reduction in risk of stroke.”
BackgroundInfluentialMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
Cranor, C. W., Bunting, B. A., & Christensen, D. B. (2003) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658003321480713 · Cited by 728
Chronic Care Clinics for Diabetes in Primary Care
Wagner, E. H., Grothaus, L. C., Sandhu, N., Galvin, M. S., McGregor, M., Artz, K., & Coleman, E. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.695 · Cited by 455
Cited by
Chrvala, C. A., Sherr, D., & Lipman, R. D. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2015.11.003 · Cited by 914
Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?
Mc Namara, K., Alzubaidi, H., & Jackson, J. K. (2019) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s133088 · Cited by 410
Machado, M., Bajcar, J., Guzzo, G. C., & Einarson, T. R. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k311 · Cited by 378
Individual patient education for people with type 2 diabetes mellitus
Duke, S.-A. S., Colagiuri, S., & Colagiuri, R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005268.pub2 · Cited by 361
Santschi, V., Chiolero, A., Colosimo, A. L., Platt, R. W., Taffé, P., Burnier, M., Burnand, B., & Paradis, G. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000718 · Cited by 349
Metadata
- Authors
- Clifford, R. M., Davis, W. A., Batty, K. T., & Davis, T. M. E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2005-04-01
- Volume
- 28
- Issue
- 4
- Pages
- 771-776
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2014958049
- Cited by
- 188
- References
- 7
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.